S-A Kim1, H Moon1, J-L Roh2, S-B Kim3, S-H Choi1, S Y Nam1, S Y Kim1. 1. Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. 2. Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. rohjl@amc.seoul.kr. 3. Internal Medicine (Oncology), Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Abstract
INTRODUCTION: Growing evidence indicates that norepinephrine promotes cancer growth and metastasis whereas β-blockers decrease these risks. This study aimed to examine the clinical impact of β-blockers and other hypertensive drugs on disease recurrence and survival in patients with head and neck squamous cell carcinoma (HNSCC). MATERIALS AND METHODS: This study analyzed a cohort of 1274 consecutive patients who received definitive treatments for previously untreated HNSCC at our tertiary referral center between January 2001 and December 2012. Antihypertensive use was considered positive if patients were on medication from HNSCC diagnosis to at least 1 year after treatment initiation. Cox proportional hazard models were utilized to determine associations between antihypertensive drugs and recurrence, survival, and second primary cancer (SPC) occurrence. RESULTS: Hypertension itself was not a significant variable of recurrence and survival and no antihypertensive drug use affected SPC occurrence (all P > 0.1). After controlling for clinical factors, calcium-channel blocker use remained an independent variable for index cancer recurrence, and β-blocker use was significantly associated with poor cancer-specific mortality, competing mortality, and all-cause mortality (all P < 0.05). β-blocker use significantly affected competing and all-cause mortalities in normotensive patients, and calcium-channel blocker use affected index cancer recurrence in normotensive patients (all P < 0.05). CONCLUSIONS: Our data show that β-blocker use is associated with decreased survival and calcium-channel blockers is associated with increased cancer recurrence in patients of HNSCC.
INTRODUCTION: Growing evidence indicates that norepinephrine promotes cancer growth and metastasis whereas β-blockers decrease these risks. This study aimed to examine the clinical impact of β-blockers and other hypertensive drugs on disease recurrence and survival in patients with head and neck squamous cell carcinoma (HNSCC). MATERIALS AND METHODS: This study analyzed a cohort of 1274 consecutive patients who received definitive treatments for previously untreated HNSCC at our tertiary referral center between January 2001 and December 2012. Antihypertensive use was considered positive if patients were on medication from HNSCC diagnosis to at least 1 year after treatment initiation. Cox proportional hazard models were utilized to determine associations between antihypertensive drugs and recurrence, survival, and second primary cancer (SPC) occurrence. RESULTS:Hypertension itself was not a significant variable of recurrence and survival and no antihypertensive drug use affected SPC occurrence (all P > 0.1). After controlling for clinical factors, calcium-channel blocker use remained an independent variable for index cancer recurrence, and β-blocker use was significantly associated with poor cancer-specific mortality, competing mortality, and all-cause mortality (all P < 0.05). β-blocker use significantly affected competing and all-cause mortalities in normotensive patients, and calcium-channel blocker use affected index cancer recurrence in normotensive patients (all P < 0.05). CONCLUSIONS: Our data show that β-blocker use is associated with decreased survival and calcium-channel blockers is associated with increased cancer recurrence in patients of HNSCC.
Entities:
Keywords:
Head and neck squamous cell carcinoma; Hypertension; Recurrence; Survival; β-Blockers
Authors: Sripal Bangalore; Sunil Kumar; Sverre E Kjeldsen; Harikrishna Makani; Ehud Grossman; Jørn Wetterslev; Ajay K Gupta; Peter S Sever; Christian Gluud; Franz H Messerli Journal: Lancet Oncol Date: 2010-11-29 Impact factor: 41.316
Authors: Erica K Sloan; Saul J Priceman; Benjamin F Cox; Stephanie Yu; Matthew A Pimentel; Veera Tangkanangnukul; Jesusa M G Arevalo; Kouki Morizono; Breanne D W Karanikolas; Lily Wu; Anil K Sood; Steven W Cole Journal: Cancer Res Date: 2010-09-07 Impact factor: 12.701
Authors: Kerstin Lang; Theodore L Drell; Antje Lindecke; Bernd Niggemann; Christian Kaltschmidt; Kurt S Zaenker; Frank Entschladen Journal: Int J Cancer Date: 2004-11-01 Impact factor: 7.396
Authors: Christopher I Li; Janet R Daling; Mei-Tzu C Tang; Kara L Haugen; Peggy L Porter; Kathleen E Malone Journal: JAMA Intern Med Date: 2013-09-23 Impact factor: 21.873
Authors: Jessica L Harding; Manoshayini Sooriyakumaran; Kaarin J Anstey; Robert Adams; Beverley Balkau; Sharon Brennan-Olsen; Tom Briffa; Timothy M E Davis; Wendy A Davis; Annette Dobson; Graham G Giles; Janet Grant; Rachel Huxley; Matthew Knuiman; Mary Luszcz; Paul Mitchell; Julie A Pasco; Christopher M Reid; David Simmons; Leon A Simons; Anne W Taylor; Andrew Tonkin; Mark Woodward; Jonathan E Shaw; Dianna J Magliano Journal: J Hypertens Date: 2016-01 Impact factor: 4.844
Authors: Ondrej Fiala; Pavel Ostasov; Ondrej Sorejs; Vaclav Liska; Tomas Buchler; Alexandr Poprach; Jindrich Finek Journal: Cancers (Basel) Date: 2019-11-25 Impact factor: 6.639
Authors: José A Carlos-Escalante; Marcela de Jesús-Sánchez; Alejandro Rivas-Castro; Pavel S Pichardo-Rojas; Claudia Arce; Talia Wegman-Ostrosky Journal: Front Oncol Date: 2021-05-20 Impact factor: 6.244